Selected research
Industry Research
Beta Blockers Industry Research Report 2026
Market perspective
The global Beta Blockers market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Beta Blockers is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Beta Blockers is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Beta Blockers is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Beta Blockers include China National Pharmaceutical Group, CHIA TAI TIANQING PHARMACEUTICAL GROUP, Gerui Pharmaceutical, Qilu Pharmaceutical, Nanjing Hicin Pharmaceutical, Merck, Hengrui Pharmaceuticals, Fosun Pharmaceutical and Beijing Huasu Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Beta Blockers market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Beta Blockers Market by Company
China National Pharmaceutical Group
CHIA TAI TIANQING PHARMACEUTICAL GROUP
Gerui Pharmaceutical
Qilu Pharmaceutical
Nanjing Hicin Pharmaceutical
Merck
Hengrui Pharmaceuticals
Fosun Pharmaceutical
Beijing Huasu Pharmaceutical
AstraZeneca
Sumitomo Pharma
Ono Pharmaceutical
Dainippon Sumitomo
Beta Blockers Segment by Type
Nonselective Beta-Blockers
Selective Beta-Blockers
Beta Blockers Segment by Application
Cardiovascular Disease
Other Non-Cardiovascular Diseases
Beta Blockers Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Beta Blockers market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Beta Blockers and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Beta Blockers.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Beta Blockers manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Beta Blockers by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Beta Blockers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nonselective Beta-Blockers
- Selective Beta-Blockers
Applications
- Cardiovascular Disease
- Other Non-Cardiovascular Diseases
Companies covered
- China National Pharmaceutical Group
- CHIA TAI TIANQING PHARMACEUTICAL GROUP
- Gerui Pharmaceutical
- Qilu Pharmaceutical
- Nanjing Hicin Pharmaceutical
- Merck
- Hengrui Pharmaceuticals
- Fosun Pharmaceutical
- Beijing Huasu Pharmaceutical
- AstraZeneca
- Sumitomo Pharma
- Ono Pharmaceutical
- Dainippon Sumitomo
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Beta Blockers Market Size (2021-2032)
- 2.2.2 Global Beta Blockers Sales (2021-2032)
- 2.2.3 Global Beta Blockers Market Average Price (2021-2032)
- 2.3 Beta Blockers by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nonselective Beta-Blockers
- 2.3.3 Selective Beta-Blockers
- 2.4 Beta Blockers by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cardiovascular Disease
- 2.4.3 Other Non-Cardiovascular Diseases
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Beta Blockers Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Beta Blockers Sales (kg) of Manufacturers (2021-2026)
- 3.3 Global Beta Blockers Revenue of Manufacturers (2021-2026)
- 3.4 Global Beta Blockers Average Price by Manufacturers (2021-2026)
- 3.5 Global Beta Blockers Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Beta Blockers, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Beta Blockers, Product Type & Application
- 3.8 Global Manufacturers of Beta Blockers, Established Date
- 3.9 Global Beta Blockers Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 China National Pharmaceutical Group
- 4.1.1 China National Pharmaceutical Group Company Information
- 4.1.2 China National Pharmaceutical Group Business Overview
- 4.1.3 China National Pharmaceutical Group Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 China National Pharmaceutical Group Beta Blockers Product Portfolio
- 4.1.5 China National Pharmaceutical Group Recent Developments
- 4.2 CHIA TAI TIANQING PHARMACEUTICAL GROUP
- 4.2.1 CHIA TAI TIANQING PHARMACEUTICAL GROUP Company Information
- 4.2.2 CHIA TAI TIANQING PHARMACEUTICAL GROUP Business Overview
- 4.2.3 CHIA TAI TIANQING PHARMACEUTICAL GROUP Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CHIA TAI TIANQING PHARMACEUTICAL GROUP Beta Blockers Product Portfolio
- 4.2.5 CHIA TAI TIANQING PHARMACEUTICAL GROUP Recent Developments
- 4.3 Gerui Pharmaceutical
- 4.3.1 Gerui Pharmaceutical Company Information
- 4.3.2 Gerui Pharmaceutical Business Overview
- 4.3.3 Gerui Pharmaceutical Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gerui Pharmaceutical Beta Blockers Product Portfolio
- 4.3.5 Gerui Pharmaceutical Recent Developments
- 4.4 Qilu Pharmaceutical
- 4.4.1 Qilu Pharmaceutical Company Information
- 4.4.2 Qilu Pharmaceutical Business Overview
- 4.4.3 Qilu Pharmaceutical Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Qilu Pharmaceutical Beta Blockers Product Portfolio
- 4.4.5 Qilu Pharmaceutical Recent Developments
- 4.5 Nanjing Hicin Pharmaceutical
- 4.5.1 Nanjing Hicin Pharmaceutical Company Information
- 4.5.2 Nanjing Hicin Pharmaceutical Business Overview
- 4.5.3 Nanjing Hicin Pharmaceutical Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Nanjing Hicin Pharmaceutical Beta Blockers Product Portfolio
- 4.5.5 Nanjing Hicin Pharmaceutical Recent Developments
- 4.6 Merck
- 4.6.1 Merck Company Information
- 4.6.2 Merck Business Overview
- 4.6.3 Merck Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Merck Beta Blockers Product Portfolio
- 4.6.5 Merck Recent Developments
- 4.7 Hengrui Pharmaceuticals
- 4.7.1 Hengrui Pharmaceuticals Company Information
- 4.7.2 Hengrui Pharmaceuticals Business Overview
- 4.7.3 Hengrui Pharmaceuticals Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hengrui Pharmaceuticals Beta Blockers Product Portfolio
- 4.7.5 Hengrui Pharmaceuticals Recent Developments
- 4.8 Fosun Pharmaceutical
- 4.8.1 Fosun Pharmaceutical Company Information
- 4.8.2 Fosun Pharmaceutical Business Overview
- 4.8.3 Fosun Pharmaceutical Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Fosun Pharmaceutical Beta Blockers Product Portfolio
- 4.8.5 Fosun Pharmaceutical Recent Developments
- 4.9 Beijing Huasu Pharmaceutical
- 4.9.1 Beijing Huasu Pharmaceutical Company Information
- 4.9.2 Beijing Huasu Pharmaceutical Business Overview
- 4.9.3 Beijing Huasu Pharmaceutical Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Beijing Huasu Pharmaceutical Beta Blockers Product Portfolio
- 4.9.5 Beijing Huasu Pharmaceutical Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Beta Blockers Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
- 4.11 Sumitomo Pharma
- 4.11.1 Sumitomo Pharma Company Information
- 4.11.2 Sumitomo Pharma Business Overview
- 4.11.3 Sumitomo Pharma Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sumitomo Pharma Beta Blockers Product Portfolio
- 4.11.5 Sumitomo Pharma Recent Developments
- 4.12 Ono Pharmaceutical
- 4.12.1 Ono Pharmaceutical Company Information
- 4.12.2 Ono Pharmaceutical Business Overview
- 4.12.3 Ono Pharmaceutical Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Ono Pharmaceutical Beta Blockers Product Portfolio
- 4.12.5 Ono Pharmaceutical Recent Developments
- 4.13 Dainippon Sumitomo
- 4.13.1 Dainippon Sumitomo Company Information
- 4.13.2 Dainippon Sumitomo Business Overview
- 4.13.3 Dainippon Sumitomo Beta Blockers Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Dainippon Sumitomo Beta Blockers Product Portfolio
- 4.13.5 Dainippon Sumitomo Recent Developments
5 Global Beta Blockers Market Scenario by Region
- 5.1 Global Beta Blockers Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Beta Blockers Sales by Region: 2021-2032
- 5.2.1 Global Beta Blockers Sales by Region: 2021-2026
- 5.2.2 Global Beta Blockers Sales by Region: 2027-2032
- 5.3 Global Beta Blockers Revenue by Region: 2021-2032
- 5.3.1 Global Beta Blockers Revenue by Region: 2021-2026
- 5.3.2 Global Beta Blockers Revenue by Region: 2027-2032
- 5.4 North America Beta Blockers Market Facts & Figures by Country
- 5.4.1 North America Beta Blockers Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Beta Blockers Sales by Country (2021-2032)
- 5.4.3 North America Beta Blockers Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Beta Blockers Market Facts & Figures by Country
- 5.5.1 Europe Beta Blockers Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Beta Blockers Sales by Country (2021-2032)
- 5.5.3 Europe Beta Blockers Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Beta Blockers Market Facts & Figures by Country
- 5.6.1 Asia Pacific Beta Blockers Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Beta Blockers Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Beta Blockers Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Beta Blockers Market Facts & Figures by Country
- 5.7.1 South America Beta Blockers Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Beta Blockers Sales by Country (2021-2032)
- 5.7.3 South America Beta Blockers Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Beta Blockers Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Beta Blockers Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Beta Blockers Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Beta Blockers Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Beta Blockers Sales by Type (2021-2032)
- 6.1.1 Global Beta Blockers Sales by Type (2021-2032) & (kg)
- 6.1.2 Global Beta Blockers Sales Market Share by Type (2021-2032)
- 6.2 Global Beta Blockers Revenue by Type (2021-2032)
- 6.2.1 Global Beta Blockers Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Beta Blockers Revenue Market Share by Type (2021-2032)
- 6.3 Global Beta Blockers Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Beta Blockers Sales by Application (2021-2032)
- 7.1.1 Global Beta Blockers Sales by Application (2021-2032) & (kg)
- 7.1.2 Global Beta Blockers Sales Market Share by Application (2021-2032)
- 7.2 Global Beta Blockers Revenue by Application (2021-2032)
- 7.2.1 Global Beta Blockers Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Beta Blockers Revenue Market Share by Application (2021-2032)
- 7.3 Global Beta Blockers Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Beta Blockers Value Chain Analysis
- 8.1.1 Beta Blockers Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Beta Blockers Production Mode & Process
- 8.2 Beta Blockers Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Beta Blockers Distributors
- 8.2.3 Beta Blockers Customers
9 Global Beta Blockers Analyzing Market Dynamics
- 9.1 Beta Blockers Industry Trends
- 9.2 Beta Blockers Industry Drivers
- 9.3 Beta Blockers Industry Opportunities and Challenges
- 9.4 Beta Blockers Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst